Real World Study Shows Neovasc's Reducer Is Safe, Efficacious In Patients With Refractory Angina

Neovasc Inc (NASDAQ:NVCN) has announced the publication of an article highlighting the long-term outcomes of patients suffering from refractory angina treated with the Neovasc Reducer system in the International Journal of Cardiology.
The study dubbed RESOURCE is an observational, retrospective registry that includes 658 patients in Europe, the U.K., and Israel.
The prespecified endpoints of the trial were the amelioration of anginal symptoms, evaluated with chest pain severity score and the rates of procedural success and complications.
At a median follow-up of 502 days after Reducer implantation, 39.7% of patients improved by more than two pain score CCS classes (primary endpoint) and 76% by more than one class.
The procedure was safe, and success was achieved in 96.7% of attempts.
No cases of intra- or periprocedural death, myocardial infarction, or cardiac tamponade were observed.
No patient required bailout conversion to open surgery.
The Reducer is a CE-marked device for refractory angina that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies.
Reducer is not approved in the U.S.
Price Action: NVCN shares are up 0.40% at $0.92 during the market trading session on the last check Friday.

To add Benzinga News as your preferred source on Google, click here.